Fig. 7
From: Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer
Knockdown of FGD4 increased drug sensitivity of prostate cancer cells. Prostate cancer cells. LNCaP-104S and PC-3 were transfected with FGD4 siRNA or control siRNAs and treated with Casodex (CDX) and docetaxel (DTX). Sensitivity of cells to specific treatments was measured through MTS assays. DMSO was used as the vehicle control. a: Percent reduction in viability of LNCaP-104S cells transfected with FGD4 siRNAs following treatment with 10μM CDX compared to cells transfected with control RNAs. Data represent mean ± SD of at least three separate experiments. *p<0.01 b: Percent reduction in viability of PC-3 cells transfected with FGD4 siRNA following treatment with 5 nM and 25 nM DTX compared to cells transfected with control RNAs. Data represent mean ± SD of three independent analyses. *p≤0.05, **p≤0.005, ***p≤0.005.